Also known as Zenagamtide
Novo Nordisk’s single-molecule GLP-1 + amylin receptor agonist (INN zenagamtide) — CagriSema’s two pathways in one peptide, in Phase 3 as a weekly injection with an oral form in development.
Research refreshed
Amycretin, now carrying the international name zenagamtide, is an investigational unimolecular agonist of both the GLP-1 and amylin receptors. Where CagriSema reaches those two satiety pathways by co-formulating two peptides, amycretin does it with one — and is being developed in both subcutaneous and oral forms. An early subcutaneous study (Lancet 2025) reported 24.3% mean weight reduction at 36 weeks on the highest dose. Novo Nordisk began the Phase 3 AMAZE obesity program in early 2026. It is not approved anywhere.
The GLP-1 and amylin pathways suppress appetite through different receptors in different parts of the brain, and engaging both is additive — the premise of CagriSema. Amycretin is Novo Nordisk’s attempt to put both activities into a single molecule, which simplifies manufacturing and dosing ratios and, critically, makes an oral version feasible in a way a two-peptide combination is not.
The early data drew attention because of how fast the weight came off. A Phase 1b/2a trial of the once-weekly subcutaneous form (Lancet 2025) reported estimated mean weight reduction of 24.3% at 36 weeks on the top dose, with no plateau at the end of treatment. A Phase 1 trial of the once-daily oral form reported about 13% at just 12 weeks. Both were small, short studies in which participants were titrated quickly, and gastrointestinal adverse events were common — the figures are signals, not Phase 3 estimates.
Phase 3 began in 2026: the AMAZE program opened its first obesity trial in February, followed by a weight-maintenance study, with the subcutaneous form leading. In type 2 diabetes, a Phase 2 trial presented at ADA 2026 reported significant HbA1c reductions with up to 14.6% weight loss. No Phase 3 efficacy data exist yet, and primary completion of the lead obesity trial is not expected for several years.
One peptide with agonist activity at both the GLP-1 receptor and amylin receptors — GLP-1-mediated insulin secretion and appetite suppression combined with amylin-mediated hindbrain satiety and slowed gastric emptying.
Behind every vial of Amycretin is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Amycretin, specifically, is brought into being.
Amycretin begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Amycretin is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — Amycretin plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Amycretin proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Amycretin — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing Amycretin to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Amycretin, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Amycretin (INN zenagamtide) is an investigational Novo Nordisk peptide that activates both the GLP-1 and amylin receptors in a single molecule. It is in Phase 3 for obesity as a once-weekly injection, with an oral version also in development.
Yes. Zenagamtide is the international nonproprietary name assigned to the compound previously known by its development name, amycretin.
Both combine GLP-1 and amylin activity. CagriSema is two separate peptides — semaglutide and cagrilintide — in one injection. Amycretin is a single peptide with both activities, which also allows an oral formulation.
An early subcutaneous trial (Lancet 2025) reported 24.3% mean weight reduction at 36 weeks on the top dose, and an oral Phase 1 trial about 13% at 12 weeks. These were small early-phase studies; Phase 3 results are not yet available.
No. It is investigational everywhere, with Phase 3 trials that began in 2026. Anything sold as amycretin today is outside any regulated channel. This page is a research reference, not medical advice.
The once-weekly GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus — FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, and MASH.
ViewThe once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).
ViewDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.